Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CV-MG01 phase 2 trial in moderate to severe myasthenia gravis
2017-000323-27Phase 2Active
- Sponsor
- CuraVac
- Start
- Apr 2017
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myasthenia gravis (MG) comparing CV-MG01 with Placebo (2 arms). Primary endpoint: Change from baseline in Quantitative Myasthenia Gravis total score. Started Apr 2017; status: active.
02
Drugs
CV-MG01
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2017-000323-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000323-27.